SHANGHAI — On April 21, 2023, OBiO Technology (Shanghai) Corp., Ltd. (“OBiO” or “the Company”), a leading gene and cell therapy CDMO in China, announced the launching of a new GMP manufacturing base, named OBiO Intelli-M. The new base was located in the China (Shanghai) Pilot Free Trade Zone, Lin-Gang Special Area, with 29 production lines and 828,000+ square feet in area, which was one of the biggest super factories for gene therapy in the world. [Read more…]
ImmuneBridge Raises $12M from M Ventures and Insight Partners to Advance Cord Blood-Derived NK Cell Immunotherapies
Biotech company taps into human diversity for next-generation NK cell therapies
SAN FRANCISCO–ImmuneBridge, a biotechnology company using nature’s innate intelligence to fight cancer, today announced the close of an oversubscribed $12 million seed financing co-led by global investors Insight Partners and M Ventures, the strategic, corporate venture capital arm of Merck KGaA, Darmstadt, Germany. One Way Ventures and Gaingels also participated. Cheryl Zimberlin, Investment Director at M Ventures, and Dylan Morris, Managing Director at Insight Partners have joined ImmuneBridge’s Board of Directors. [Read more…]
Dr. Robert Hariri on Cell Therapeutics, Combination Therapies, and COVID-19
With greater than 30 million cases and 946,000 deaths reported from COVID-19 worldwide, the novel Coronavirus represents one of the largest pandemics in modern history. Thankfully, it also represents the largest cooperative effort in human history.
Globally, scientists are exploring every potential weapon to suppress the threat, including vaccines, repurposed drugs, combination therapies, and as we explore here, cellular therapies with promising cell types such as natural killer (NK) cells and mesenchymal stem cells (MSCs).
In this interview with Dr. Robert Hariri, CEO of Celularity, Inc., we discuss the company’s cell therapeutics pipeline against COVID-19. Enjoy! [Read more…]
Center for Breakthrough Medicines, Nucleus Biologics, and Stoic Bio Announce Strategic Collaboration for Steady Supply of Quality Controlled Cell Culture Media to Expedite Development of Cell and Gene Therapies
March 7, 2023, SAN DIEGO, CA — In a joint effort to accelerate high-quality therapies to market, Nucleus Biologics, The Cell Performance Company™, a leading provider of custom cell culture media solutions for the cell and gene therapy industry, and Stoic Bio, a provider of sustainable technology for cell media manufacturing, have announced plans for a supply agreement with the Center for Breakthrough Medicines (CBM), a leading contract development and manufacturing organization (CDMO), whose mission is to save lives by accelerating the development and manufacture of advanced therapies. This agreement makes Nucleus Biologics the preferred supplier of cell culture media and other critical biological solutions for CBM; thus, ensuring a steady, consistent supply of this critical material with tighter quality control measures. [Read more…]
Caribou Biosciences Granted FDA RMAT and Fast Track Designations for CB-010, an Allogeneic Anti-CD19 CAR-T Cell Therapy
RMAT and Fast Track designations follow CB-010’s durable complete responses at dose level 1 in the ANTLER Phase 1 trial
CB-010 is the 1st allogeneic CAR-T cell therapy in the clinic with a PD-1 knockout
- « Previous Page
- 1
- …
- 31
- 32
- 33
- 34
- 35
- …
- 62
- Next Page »